• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtech veteran Tatyana Beldock joins Dyve Biosciences board

April 11, 2023 By Sean Whooley

Dyve Bioscience logoDyve Biosciences announced today that Tatyana Beldock joined the company’s board of directors.

Camarillo, California-based Dyve develops the DMAX delivery platform. Its transdermal drug delivery technology directly targets the acidic microenvironments that drive cancer cell growth and inflammation.

“We are thrilled to have Tatyana join our board,” said Dr. Ryan Beal, CEO of Dyve. “Tatyana brings a wealth of business, investment, and strategic experience to our team. I look forward to working side-by-side with her as we advance our immunology and oncology assets through the clinics and expand our strategic partnerships.”

Beldock brings with her more than 25 years of operating and financial experience in healthcare. Her track record covers fueling growth, advancing technology and increasing shareholder value. She spent time in biopharmaceuticals, health technology, medical devices and financials.

Among previous employers are Johnson & Johnson, Pfizer, J.P. Morgan and Citigroup, as well as a number of startups. Beldock currently serves as founder and managing partner at FireRock Advisors.

“Joining the Dyve Board of Directors is a wonderful opportunity to contribute to developing multiple breakthrough therapies for patients,” said Beldock. “Dyve’s platform science has shown tremendous potential in treating immuno-inflammatory and oncologic diseases. I’m excited to join the talented group of Dyve board directors and participate in this important work.”

Filed Under: Business/Financial News, Drug-Device Combinations, Oncology, Personnel, Pharmaceuticals Tagged With: dyvebioscience, Personnel Moves

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS